Questcor (QCOR) Sees Multi-Billion Market Opportunity for Acthar in MS, IS, NS Patients
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Join SI Premium – FREE
Questcor (Nasdaq: QCOR) is trading higher Wednesday following presentation of data from the company for its Acthar drug at the Jefferies 2012 Global Healthcare Conference in New York.
Data show that paid vials for nephrotic syndrome, (NS) were 100 to 110 in May, from 94 in April, multiple sclerosis (MS) at 360 to 370 in May, from 339 the prior month, and infantile spasms (IS) to a range of 30 to 35, from 31 in April. Overall, shipped vials in May expected at 1,560, from 1,350 in April.
Total market opportunity for Acthar is $3 billion.
Estimated annualized net sales run rate for Acthar is the following:
Data show that paid vials for nephrotic syndrome, (NS) were 100 to 110 in May, from 94 in April, multiple sclerosis (MS) at 360 to 370 in May, from 339 the prior month, and infantile spasms (IS) to a range of 30 to 35, from 31 in April. Overall, shipped vials in May expected at 1,560, from 1,350 in April.
Total market opportunity for Acthar is $3 billion.
Estimated annualized net sales run rate for Acthar is the following:
- MS - $160 million to $175 million
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acrivon Therapeutics (ACRV) Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Rimini Street (RMNI) Appoints Steve Hershkowitz as Chief Revenue Officer
- Arvinas Inc. (ARVN) Appoints Randy Teel as Chief Business Officer
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
